newsfilter
← Latest News
Business Wire·

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

-- RTW Committed $75M in Launch Funding, Subject to U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI -- -- Royalties Based on Annual Net Sales of MOLBREEVI in the U.S. -- -- Funds Will Strengthen the